This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Spano, J.-P. Articles by Khayat, D. Search for Related Content PubMed PubMed Citation Articles by Spano, J.-P. Articles by Khayat, D.

Treatment Options for Anemia, Taking Risks into Consideration: Erythropoiesis-Stimulating Agents Versus Transfusions

Department of Medical Oncology, Pitié-Salpétrière Hospital, Pierre & Marie Curie University, Paris, France

Key Words. Anemia • Erythropoiesis-stimulating agents • Transfusions

Correspondence: Jean-Philippe Spano, M.D., Ph.D., Département d'Oncologie Médicale, Groupe Hospitalier Pitié-Salpétrière, 47 Boulevard de l'Hôpital, 75013 Paris, France. Telephone: 33-1-42-16-04-52; Fax: 33-1-42-16-04-65; e-mail: jean-philippe.spano{at}psl.aphp.fr

Disclosure: No potential conflicts of interest were reported by the author, planners, reviewers, or staff managers of this article.

Erythropoiesis-stimulating agents are indicated for the treatment of chemotherapy induced-anemia in cancer patients. Controlled clinical studies have shown that epoetin alfa consistently and significantly increases levels of hemoglobin (Hb), decreases the need for RBC transfusion, and improves the quality of life that is of such importance in cancer patients with a limited life expectancy. The rise achieved in Hb level correlates with an improvement in quality of life. Studies have also demonstrated that earlier initiation of epoetin therapy (i.e., starting treatment at an Hb level of 10–11 g/dl rather than waiting for Hb to fall to <10 g/dl) is associated with a faster achievement of an optimal Hb level, a lower transfusion requirement, and a maintained quality of life.

This article has been cited by other articles:

				B. K. Hadland and G. D. Longmore Erythroid-Stimulating Agents in Cancer Therapy: Potential Dangers and Biologic Mechanisms J. Clin. Oncol., September 1, 2009; 27(25): 4217 - 4226. [Abstract] [Full Text] [PDF]

				M. Tsuboi, K. Ezaki, K. Tobinai, Y. Ohashi, and N. Saijo Weekly Administration of Epoetin Beta for Chemotherapy-induced Anemia in Cancer Patients: Results of a Multicenter, Phase III, Randomized, Double-blind, Placebo-controlled Study Jpn. J. Clin. Oncol., March 1, 2009; 39(3): 163 - 168. [Abstract] [Full Text] [PDF]

				M. S. Aapro Editorial: Anemia Management with Erythropoiesis-Stimulating Agents: A Risk-Benefit Update Oncologist, May 1, 2008; 13(suppl_3): 1 - 3. [Full Text] [PDF]